Nuwellis, Inc. (NUWE)

Findings reinforce Nuwellis' leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload. Findings reinforce Nuwellis' leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload.

Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases Pediatric nephrology and cardiology teams continue to seek out Aquadex for safe, precise fluid management in complex cases

Nuwellis (NASDAQ: NUWE - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership. Valuation and Earnings This table compares Nuwellis and Edwards

Nuwellis, Inc. ( NUWE ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Leah McMullen - Director of Communications John Erb - Interim CFO, Interim Principal Financial & Accounting Officer, CEO, President and Chairman Lynn Blake Presentation Operator Good day, everyone, and welcome to today's Nuwellis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's call will be recorded, and I will be standing by should you need any assistance.

MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today reported financial results for the third quarter ended September 30, 2025 and provided a business update on recent milestones advancing the company's cardiorenal growth strategy. Third Quarter 2025 Highlights Total revenue of $2.2 million, down 6% year-over-year and up 29% sequentially, reflecting increased consumable utilization and stronger U.S. console sales on a sequential quarter basis.

MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that the United States Patent and Trademark Office has issued Nuwellis a notice of allowance for a new patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems, including the company's Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System currently in development. Many extracorporeal blood filtration systems rely on automated clamps as part of their safety design to prevent air embolism or pressure imbalances.

MINNEAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that it will release financial results for the third quarter 2025 on November 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.

ULTRA-Peds Registry, the largest multi-center dataset of its kind, shows Aquadex therapy was well-tolerated in critically ill children, a population with extremely limited treatment options Results highlight life-threatening gaps in pediatric care and underscore Nuwellis' commitment to pediatric innovation and integrated cardio-renal care MINNEAPOLIS, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced findings from the ULTRA-Peds registry, a multi-center observational study examining the real-world use of the Aquadex System in children with acute kidney injury (AKI), fluid overload, or congenital kidney failure.

EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

Watch the “What This Means” segment here

MINNEAPOLIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, announced plans to introduce a new 24-hour circuit for Aquadex therapy in the United States this fall.

MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC).

Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal

MINNEAPOLIS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Thursday, August 21, 2025 at 2:40 PM ET Presenter: John Erb, President and Chief Executive Officer Registration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology.

Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2025 Earnings Conference Call August 14, 2025 9:00 AM ET Company Participants John L. Erb - CEO, President & Chairman of the Board Leah McMullen - Corporate Participant Robert B.

MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company dedicated to transforming care for fluid overload patients, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.